Item 8.01 Other Events.

On June 24, 2020, Castle Biosciences, Inc. (the "Company"), entered into an underwriting agreement with SVB Leerink LLC and Robert W. Baird & Co. Incorporated, as representatives of the several underwriters named in Schedule A thereto (the "Underwriters"), relating to the public offering of 2,000,000 shares of the Company's common stock. The public offering price of each share of common stock was $37.00. The offering closed on June 29, 2020. The Underwriters have an option to purchase up to an additional 300,000 share of common stock at the public offering price, less underwriting discounts and commissions, through July 24, 2020.

The gross proceeds to the Company, before deducting underwriting discounts and commissions and other offering expenses, were $74.0 million.

The offering was made only by means of a prospectus forming a part of the effective registration statements (File Nos. 333-239354 and 333-239418) relating to the offering of these securities.

The disclosures in this Current Report on Form 8-K shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. --------------------------------------------------------------------------------

© Edgar Online, source Glimpses